What the FDA labels say about taking them together
Adalimumab and adalimumab-afzb
Adalimumab-afzb's FDA label of May 6, 2026 names adalimumab in its boxed warning section; the adalimumab labels PlainMeds reads (4) do not name adalimumab-afzb. The adalimumab-afzb label: “Although MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either ABRILADA or MTX.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the adalimumab-afzb FDA label on DailyMed (effective May 6, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the adalimumab label say about adalimumab-afzb?
Adalimumab's label (effective October 21, 2025) and its 3 other brand-application labels do not name adalimumab-afzb in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-afzb label say about adalimumab?
Adalimumab-afzb label, boxed warningSERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including ABRILADA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ].
Adalimumab-afzb label, drug interactionsAlthough MTX reduced the apparent clearance of adalimumab, the data do not suggest the need for dose adjustment of either ABRILADA or MTX [see Clinical Pharmacology (12.3) ].
Adalimumab-afzb label, warnings and precautionsPatients treated with adalimumab products, including ABRILADA, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Source: FDA drug label (ABRILADA), Pfizer Laboratories Div Pfizer Inc, effective May 6, 2026 (SPL set 5ef1c7cf-466f-495e-8d13-82e2ddfa7a4f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-afzb | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once